Hunter syndrome (Muccopolysaccharridosis Type II) in Macedonia and Bulgaria.

BACKGROUND Mucopolysaccharidosis II (MPS II) is caused by a deficiency of iduronate-2-sulfatase (IDS; EC 3.1.6.13). METHODS AND RESULTS We describe 11 boys from Bulgaria and Macedonia detected in the period from 1998 to 2008. The mean age at diagnosis was 4.77+/-1.29 years. All children were severely retarded: IQ ranged from 34-80, and they all had coarse faces and hepatomegaly. In addition, splenomegaly was found in 81.81% patients, dysostosis in 45.45%, kyphosis in 27.27%, deafness in 18.08%, growth below the third percentile in 45.45%, growth below the parental target height in all patients, stiff joints in 56.56% and hypertrophic myocardiopathy in 18.18% children. Two patients died at the age of 11 and 35 years. Plasma iduronate-2-sulfatase was low in all probands and normal in parents and relatives. Two new mutations were discovered: p.K236N (c.708G>C) in a child with a moderately severe phenotype, and p.Q80K (c.238C>A) which resulted in a severe phenotype and early death at the age of 11 years. Heterozygote carriers of the pathogenic allele were 29 female relatives. The calculated incidence rate for MPS II in Macedonia (censuses 1994 and 2002, children under 14 years: 483,923 and 426,280) and Bulgaria (censuses 1992 and 2006, children under 14 years: 1 126, 598 and 1,077,020) are 0.36 and 0.46 respectively, while the calculated prevalence rate are 3.6 and 4.6 per 1,000,000 boys (aged 0-14 years). Correlating phenotype and genotype remains a complex endeavour. CONCLUSIONS We report calculated incidence and prevalence rates in two South Eastern European countries, and 2 novel genetic alterations correlated with their phenotypes.

[1]  C. Lam,et al.  Molecular investigations of a novel iduronate-2-sulfatase mutant in a Chinese patient. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[2]  P. Tanpaiboon,et al.  Molecular analysis of the iduronate-2-sulfatase gene in Thai patients with Hunter syndrome , 2008, Journal of Inherited Metabolic Disease.

[3]  V. Bours,et al.  Molecular analysis in two siblings African patients with severe form of Hunter Syndrome: identification of a novel (p.Y54X) nonsense mutation. , 2007, Journal of tropical pediatrics.

[4]  Ya-xian Meng,et al.  A new mutation (1062 del 16) of iduronate-2-sulfatase gene from a Chinese patient with hunter syndrome , 2007, Journal of Zhejiang University SCIENCE B.

[5]  R. Giugliani,et al.  A clinical study of 77 patients with mucopolysaccharidosis type II , 2007, Acta paediatrica.

[6]  X. Gu,et al.  [Detection of two novel mutations of iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II]. , 2007, Yi chuan = Hereditas.

[7]  S. Alves,et al.  Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations , 2006, Journal of Inherited Metabolic Disease.

[8]  D. Lin,et al.  Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[9]  B. Bembi,et al.  Multiple cryptic splice sites can be activated by IDS point mutations generating misspliced transcripts , 2006, Journal of Molecular Medicine.

[10]  C. Du,et al.  [Detection of a new mutation (1343-TT) in the iduronate-2-sulfatase gene from a Chinese patient with mucopolysaccharidosis type II]. , 2006, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[11]  Shuan-Pei Lin,et al.  Expression studies of mutations underlying Taiwanese Hunter syndrome (mucopolysaccharidosis type II) , 2005, Human Genetics.

[12]  O. V. van Diggelen,et al.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease) , 2001, Journal of Inherited Metabolic Disease.

[13]  T. Fukao,et al.  Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese patients with mucopolysaccharidosis type II (Hunter disease) , 1998, Journal of Inherited Metabolic Disease.

[14]  C. P. Morris,et al.  The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II — Hunter syndrome) , 1991, Human Genetics.

[15]  C. P. Morris,et al.  Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome , 1991, Human Genetics.

[16]  R. Lowry,et al.  An update on the frequency of mucopolysaccharide syndromes in British Columbia , 1990, Human Genetics.

[17]  P. Harper,et al.  Incidence of Hunter's syndrome , 2004, Human Genetics.

[18]  J. Nelson,et al.  Incidence of the mucopolysaccharidoses in Western Australia , 2003, American journal of medical genetics. Part A.

[19]  S. Regis,et al.  Expression studies of two novel in CIS‐mutations identified in an intermediate case of Hunter syndrome , 2003, American journal of medical genetics. Part A.

[20]  Junjiang Fu,et al.  [The detection of the frequent mutations of iduronate-2-sulphatase gene in mucopolysaccharidosis type II patients in Chinese]. , 2002, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[21]  F. Corsolini,et al.  Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: New mutations in the iduronate‐2‐sulfatase (IDS) gene , 2001, Human mutation.

[22]  R. Giugliani,et al.  Clinical and laboratorial study of 19 cases of mucopolysaccharidoses. , 2000, Revista do Hospital das Clinicas.

[23]  S. Karsten,et al.  Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients , 1998, Human Genetics.

[24]  E. Vafiadaki,et al.  Mutation analysis in 57 unrelated patients with MPS II (Hunter’s disease) , 1998, Archives of disease in childhood.

[25]  D. Bozon,et al.  Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients , 1998, Clinical genetics.

[26]  W. Hwu,et al.  Mucopolysaccharidosis type II (Hunter's syndrome) in Taiwan. , 1998, Journal of the Formosan Medical Association = Taiwan yi zhi.

[27]  N. Kondo,et al.  [Mucopolysaccharidosis type II (Hunter syndrome)]. , 1998, Ryoikibetsu shokogun shirizu.

[28]  M. Grosso,et al.  Detection of four novel mutations in the iduronate‐2‐sulfatase gene , 1998, Human mutation.

[29]  J. Nelson,et al.  Incidence of the mucopolysaccharidoses in Northern Ireland , 1997, Human Genetics.

[30]  R. Gibbs,et al.  Molecular and phenotypic variation in patients with severe Hunter syndrome. , 1997, Human molecular genetics.

[31]  H. Kresse,et al.  Mucopolysaccharidosis type II (Hunter syndrome): mutation "hot spots" in the iduronate-2-sulfatase gene. , 1996, American journal of human genetics.

[32]  R. Carrozzo,et al.  Two New Nonsense mutations (Q80X; Q389X) in patients with severe hunter syndrome ( mucopolysaccharidosis type II) , 1996, Human mutation.

[33]  B. Winchester,et al.  Mutation analysis in 20 patients with Hunter disease , 1996, Human mutation.

[34]  E. Schwinger,et al.  Mutations of the iduronate‐2‐sulfatase gene in 12 Polish. Patients with mucopolysaccharidosis type II (Hunter syndrome) , 1995, Human mutation.

[35]  K. Wulff,et al.  Mutations of the iduronate‐2‐sulfatase (IDS) gene in patients with hunter syndrome (mucopolysaccharidosis II) , 1994, Human mutation.

[36]  C. P. Morris,et al.  Iduronate-2-sulfatase gene mutations in 16 patients with mucopolysaccharidosis type II (Hunter syndrome). , 1993, Human molecular genetics.

[37]  R. Anderson,et al.  Caveat to genotype–phenotype correlation in mucopolysaccharidosis type II: Discordant clinical severity of R468W and R468Q mutations of the iduronate‐2‐sulfatase gene , 1993, Human mutation.

[38]  E. Schwinger,et al.  Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate‐2‐sulphatase gene , 1993, Human mutation.

[39]  E. Schwinger,et al.  Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome). , 1992, Human molecular genetics.

[40]  D. Bentley,et al.  Detection of point mutations and a gross deletion in six Hunter syndrome patients. , 1992, Genomics.

[41]  R. Wevers,et al.  Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. , 1989, Clinical chemistry.

[42]  P. Benson,et al.  PRENATAL DIAGNOSIS OF TWO HURLER FETUSES USING AN IMPROVED ASSAY FOR METHYLUMBELLIFERYL-α-L-IDURONEDASE , 1979, The Lancet.

[43]  P. Benson,et al.  Prenatal diagnosis of two Hurler fetuses using an improved assay for methylumbelliferyl-alpha-L-iduronidase. , 1979, Lancet.

[44]  N. Chamoles,et al.  Sequential thin layer chromatography of urinary acidic glycosaminglycans. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[45]  M. Ho,et al.  Stimulation of acid β-galactosidase activity by chloride ions , 1970 .

[46]  M. Ho,et al.  Stimulation of acid beta-galactosidase activity by chloride ions. , 1970, Clinica chimica acta; international journal of clinical chemistry.

[47]  K. S. Dodgson,et al.  The assay of arylsulphatases A and B in human urine. , 1959, Clinica chimica acta; international journal of clinical chemistry.